NASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $71.44 +4.49 (+6.71%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$71.14 -0.30 (-0.42%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About DexCom Stock (NASDAQ:DXCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DexCom alerts:Sign Up Key Stats Today's Range$66.30▼$71.4850-Day Range$57.56▼$71.4452-Week Range$54.11▼$89.98Volume11.24 million shsAverage Volume6.26 million shsMarket Capitalization$27.57 billionP/E Ratio30.53Dividend YieldN/APrice Target$82.21Consensus RatingModerate Buy Company Overview DexCom, Inc. is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring. Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations. The company’s product portfolio includes commercially marketed systems—most notably its G6 and G7 families—which are intended to simplify sensor insertion, extend wearable life and improve ease of use. These systems are used in both personal and professional settings, including by patients at home and by clinicians who monitor glucose remotely. DexCom’s CGM ecosystem emphasizes connectivity and interoperability. Its devices support mobile apps for real-time glucose display and data sharing with caregivers, and are designed to integrate with insulin delivery systems and other digital health platforms to enable automated or guided diabetes management workflows. The company also invests in software and data analytics to enhance actionable insights for users and providers. Operating commercially in the United States and across multiple international markets, including Europe and parts of the Asia‑Pacific region, DexCom pursues expanded access through reimbursement initiatives, partnerships and regulatory approvals. The company has emphasized ongoing research and development aimed at improving sensor accuracy, user convenience and the broader clinical applications of continuous glucose monitoring. It is led by CEO Kevin Sayer and a management team focused on device innovation and global commercial growth.AI Generated. May Contain Errors. Read More DexCom Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreDXCM MarketRank™: DexCom scored higher than 84% of companies evaluated by MarketBeat, and ranked 89th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 19 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialDexCom has a consensus price target of $82.21, representing about 15.1% upside from its current price of $71.44.Amount of Analyst CoverageDexCom has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth17.90% Earnings GrowthEarnings for DexCom are expected to grow by 17.90% in the coming year, from $2.57 to $3.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 30.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 30.53, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.81.Price to Earnings Growth RatioDexCom has a PEG Ratio of 1.11. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 9.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.76% of the float of DexCom has been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 3.96, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 20.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.71 News SentimentDexCom has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 41 news articles for DexCom this week, compared to 12 articles on an average week.Search Interest26 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $379,990.00 in company stock.Percentage Held by Insiders0.28% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXCM Stock News HeadlinesLive Longer and Better. Does Medicine’s New Obsession Really Work?1 hour ago | finance.yahoo.comThe DexCom Stock Turnaround Is Showing Real Signs of LifeMay 20 at 1:51 PM | barchart.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker. | Paradigm Press (Ad)Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 1,700 Shares of StockMay 20 at 6:49 AM | insidertrades.comDXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in GermanyMay 19 at 12:43 PM | finance.yahoo.comBridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) StockMay 15, 2026 | insidertrades.comSell in May and Go Away—Starting With These 3 Stocks (DXCM)Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.May 12, 2026 | marketbeat.com3 Reasons Analysts Love DexComContinuous glucose monitoring devices are vital to those with type 2 diabetes, and DexCom is cementing its position as a leader in this growing market.May 5, 2026 | marketbeat.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $66.37 at the start of the year. Since then, DXCM stock has increased by 7.6% and is now trading at $71.44. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, April, 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.09. The company's quarterly revenue was up 15.0% on a year-over-year basis. Read the conference call transcript. When did DexCom's stock split? Shares of DexCom split before market open on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? The following companies are subsidiaries of DexCom: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? Top institutional investors of DexCom include Janus Henderson Group PLC (0.69%), Arrowstreet Capital Limited Partnership (0.66%), SG Americas Securities LLC (0.54%) and DSM Capital Partners LLC (0.50%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Michael Jon Brown, Sadie Stern, Barry J Regan, Steven R Altman, Mark G Foletta, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Richard Alexander Collins, Nicholas Augustinos, Bridgette P Heller and Kyle Malady. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings4/30/2026Today5/21/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 6 days, DXCM's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees11,000Year Founded1999Price Target and Rating Average Price Target for DexCom$82.21 High Price Target$102.00 Low Price Target$64.00 Potential Upside/Downside+15.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$2.34 Trailing P/E Ratio30.53 Forward P/E Ratio27.80 P/E Growth1.11Net Income$836.30 million Net Margins19.31% Pretax Margin24.98% Return on Equity33.33% Return on Assets13.19% Debt Debt-to-Equity Ratio0.42 Current Ratio1.95 Quick Ratio1.64 Sales & Book Value Annual Sales$4.66 billion Price / Sales5.91 Cash Flow$2.95 per share Price / Cash Flow24.18 Book Value$7.66 per share Price / Book9.33Miscellaneous Outstanding Shares385,870,000Free Float384,793,000Market Cap$27.57 billion OptionableOptionable Beta1.40 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:DXCM) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
